全文获取类型
收费全文 | 43087篇 |
免费 | 2095篇 |
国内免费 | 1400篇 |
出版年
2023年 | 658篇 |
2022年 | 946篇 |
2021年 | 1174篇 |
2020年 | 1246篇 |
2019年 | 1652篇 |
2018年 | 1546篇 |
2017年 | 995篇 |
2016年 | 1004篇 |
2015年 | 1098篇 |
2014年 | 2519篇 |
2013年 | 3704篇 |
2012年 | 1797篇 |
2011年 | 2640篇 |
2010年 | 1890篇 |
2009年 | 2033篇 |
2008年 | 2063篇 |
2007年 | 2099篇 |
2006年 | 1898篇 |
2005年 | 1711篇 |
2004年 | 1466篇 |
2003年 | 1226篇 |
2002年 | 1078篇 |
2001年 | 604篇 |
2000年 | 551篇 |
1999年 | 554篇 |
1998年 | 470篇 |
1997年 | 411篇 |
1996年 | 402篇 |
1995年 | 403篇 |
1994年 | 333篇 |
1993年 | 326篇 |
1992年 | 272篇 |
1991年 | 272篇 |
1990年 | 217篇 |
1989年 | 196篇 |
1988年 | 175篇 |
1987年 | 169篇 |
1985年 | 393篇 |
1984年 | 643篇 |
1983年 | 499篇 |
1982年 | 500篇 |
1981年 | 403篇 |
1980年 | 362篇 |
1979年 | 305篇 |
1978年 | 267篇 |
1977年 | 266篇 |
1976年 | 243篇 |
1975年 | 197篇 |
1974年 | 161篇 |
1973年 | 190篇 |
排序方式: 共有10000条查询结果,搜索用时 15 毫秒
21.
《Harmful algae》2016
Cyanobacteria are one of the principal sources of volatile organic compounds (VOCs) which cause offensive taste and odor (T&O) in drinking and recreational water, fish, shellfish and other seafood. Although non-toxic to humans, these T&O compounds severely undermine public trust in these commodities, resulting in substantial costs in treatment, and lost revenue to drinking water, aquaculture, food and beverage and tourist/hospitality industries. Mitigation and control have been hindered by the complexity of the communities and processes which produce and modify T&O events, making it difficult to source-track the major producer(s) and the factors governing VOC production and fate. Over the past decade, however, advances in bioinformatics, enzymology, and applied detection technologies have greatly enhanced our understanding of the pathways, the enzymes and the genetic coding for some of the most problematic VOCs produced by cyanobacteria. This has led to the development of tools for rapid and sensitive detection and monitoring for the VOC production at source, and provided the basis for further diagnostics of endogenous and exogenous controls. This review provides an overview of current knowledge of the major cyanobacterial VOCs, the producers, the biochemistry and the genetics and highlight the current applications and further research needs in this area. 相似文献
22.
23.
《Journal of molecular biology》2021,433(17):166665
Transient receptor potential melastatin 4 (TRPM4) is a broadly expressed Ca2+ activated monovalent cation channel that contributes to the pathophysiology of several diseases.For this study, we generated stable CRISPR/Cas9 TRPM4 knockout (K.O.) cells from the human prostate cancer cell line DU145 and analyzed the cells for changes in cancer hallmark functions. Both TRPM4-K.O. clones demonstrated lower proliferation and viability compared to the parental cells. Migration was also impaired in the TRPM4-K.O. cells. Additionally, analysis of 210 prostate cancer patient tissues demonstrates a positive association between TRPM4 protein expression and local/metastatic progression. Moreover, a decreased adhesion rate was detected in the two K.O. clones compared to DU145 cells.Next, we tested three novel TRPM4 inhibitors with whole-cell patch clamp technique for their potential to block TRPM4 currents. CBA, NBA and LBA partially inhibited TRPM4 currents in DU145 cells. However, none of these inhibitors demonstrated any TRPM4-specific effect in the cellular assays.To evaluate if the observed effect of TRPM4 K.O. on migration, viability, and cell cycle is linked to TRPM4 ion conductivity, we transfected TRPM4-K.O. cells with either TRPM4 wild-type or a dominant-negative mutant, non-permeable to Na+. Our data showed a partial rescue of the viability of cells expressing functional TRPM4, while the pore mutant was not able to rescue this phenotype. For cell cycle distribution, TRPM4 ion conductivity was not essential since TRPM4 wild-type and the pore mutant rescued the phenotype.In conclusion, TRPM4 contributes to viability, migration, cell cycle shift, and adhesion; however, blocking TRPM4 ion conductivity is insufficient to prevent its role in cancer hallmark functions in prostate cancer cells. 相似文献
24.
25.
《Cell reports》2020,30(4):1129-1140.e5
- Download : Download high-res image (253KB)
- Download : Download full-size image
26.
The cdc6 mutants of Schizosaccharomyces pombe have been classified as being defective in progression through the G2 phase of the cell cycle. We cloned an S. pombe gene that could complement the temperature-sensitive growth of the cdc6-23 mutant. Unexpectedly, the cloned gene was allelic to pol3, which encodes the catalytic subunit of DNA polymerase δ. Integration mapping confirmed that cdc6 and pol3 are identical. The cdc6-23 mutant carries one amino acid substitution in the conserved N3 region of Pol3.
Received: 17 October 1996 / Accepted: 19 November 1996 相似文献
27.
Glucoraphasatin is an atypical glucosinolate mainly found in Raphanus sativus roots and sprouts. This review focuses on the chemistry, the occurrence, and the biological properties of glucoraphasatin. 相似文献
28.
《Cell reports》2020,30(5):1504-1514.e7
- Download : Download high-res image (117KB)
- Download : Download full-size image
29.
Phytochemical analysis of dried twigs of Marsdenia roylei (family Asclepiadaceae) has resulted in the isolation of a trisaccharide, maryal, and a diglycoside, rolinose. Their structures were determined as O-beta-D-oleandropyranosyl-(1-->4)-O-beta-D-digitoxopyranosyl++ +-(1-->4)-D- cymaral and ethyl O-beta-D-oleandropyranosyl-(1-->4)-O-3-O-methyl-6-deoxy-beta-D- allopyranoside, respectively, by chemical degradation and spectroscopic methods. 相似文献
30.
Interleukin (IL)-6, a cytokine featuring redundancy and pleiotropic activity, contributes to host defense against acute environmental stress, while dysregulated persistent IL-6 production has been demonstrated to play a pathological role in various autoimmune and chronic inflammatory diseases. Targeting IL-6 is thus a rational approach to the treatment of these diseases. Indeed, clinical trials of tocilizumab, a humanized anti-IL-6 receptor antibody have verified its efficacy and tolerable safety for patients with rheumatoid arthritis, Castleman''s disease and systemic juvenile idiopathic arthritis, resulting in approval of this innovative biologic for treatment of these diseases. Moreover, a considerable number of case reports and pilot studies of off-label use of tocilizumab point to the beneficial effects of tocilizumab for a variety of other phenotypically different autoimmune and chronic inflammatory diseases. Elucidation of the source of IL-6 and of mechanisms through which IL-6 production is dysregulated can thus be expected to lead to clarification of the pathogenesis of various diseases. 相似文献